Case number 1:24-cv-00082
Boehringer Ingelheim Pharmaceuticals Inc. et al v. Mylan Pharmaceuticals Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| May 7, 2025 | 60 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Documents produced on 4.22.25). (O'Brien, William) (Entered: 05/07/2025) (1) |
| May 7, 2025 | 59 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Mylan's Supplemental Objections and Responses to Plaintiffs' First Set of Interrogatories to Mylan (Nos. 4, 7)). (O'Brien, William) (Entered: 05/07/2025) (1) |
| May 7, 2025 | 58 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Mylan's Objections and Responses to Plaintiffs' Second Set of Requests for Admission (Nos. 41-80)). (O'Brien, William) (Entered: 05/07/2025) (1) |
| May 7, 2025 | 57 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Mylan's Objections and Responses to Plaintiffs' Second Set of Interrogatories to Mylan (Nos. 12-25)). (O'Brien, William) (Entered: 05/07/2025) (1) |
| Feb 21, 2025 | N/A | Cases associated: Create association to 1:20-cv-00019-TSK. (dk) (Entered: 02/21/2025) (0) |
| Feb 21, 2025 | 56 | ORDER CONSOLIDATING ACTIONS AND RESCHEDULING PRETRIAL CONFERENCE AND TRIAL. The above-captioned cases are CONSOLIDATED, with Case No. 1:20-CV-19 designated as the LEAD CASE. The parties and the Clerk are DIRECTED to file all documents in the lead case. The motion for status conference in Case No. 1:24cv82 is DENIED AS MOOT (ECF No. 55 ). Signed by Chief District Judge Thomas S Kleeh on 2/21/2025. (dk) (Entered: 02/21/2025) (2) |
| Jan 21, 2025 | 55 | MOTION FOR STATUS CONFERENCE re 54 Report of Rule 26(f) Planning Meeting by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited. (O'Brien, William) (Entered: 01/21/2025) (3) |
| Jan 17, 2025 | 54 | REPORT of Rule 26(f) Planning Meeting. (Pogue, David) (Entered: 01/17/2025) (16) |
| Jan 16, 2025 | 53 | STIPULATION AND [PROPOSED] ORDER TO MODIFY DEADLINE FOR PLANNING MEETING REPORT by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited. (O'Brien, William) (Entered: 01/16/2025) (2) |
| Jan 10, 2025 | 52 | JOINT STIPULATION AND ORDER TO MODIFY DEADLINE FOR PLANNING MEETING REPORT. Rule 26 Meeting Report due by 1/16/2025. Signed by Chief District Judge Thomas S Kleeh on 1/10/2025. (dk) (Entered: 01/10/2025) (2) |
| Jan 10, 2025 | 51 | STIPULATION AND [PROPOSED] ORDER TO MODIFY DEADLINE FOR PLANNING MEETING REPORT by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited. (O'Brien, William) (Entered: 01/10/2025) (2) |
| Jan 8, 2025 | 50 | JOINT STIPULATION AND ORDER TO MODIFY DEADLINE FOR PLANNING MEETING REPORT. Rule 26 Meeting Report due by 1/10/2025. Signed by Chief District Judge Thomas S Kleeh on 1/8/2025. (dk) (Entered: 01/08/2025) (2) |
| Jan 8, 2025 | 49 | STIPULATION AND [PROPOSED] ORDER TO MODIFY DEADLINE FOR PLANNING MEETING REPORT by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited. (O'Brien, William) (Entered: 01/08/2025) (2) |
| Jan 3, 2025 | 48 | CERTIFICATE OF SERVICE by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs' First Set of Requests to Mylan for the Production of Documents and Things (Nos. 1-78). (Pogue, David) (Entered: 01/03/2025) (1) |
| Jan 3, 2025 | 47 | CERTIFICATE OF SERVICE by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs First Set of Interrogatories to Mylan (Nos. 1-11). (Pogue, David) (Entered: 01/03/2025) (1) |
| Dec 23, 2024 | 46 | JOINT STIPULATION AND ORDER TO MODIFY DEADLINE FOR PLANNING MEETING REPORT. The Court ORDERS that the deadline for the parties' Initial Planning Meeting Report and Scheduling Order Checklist is extended to January 8, 2025. Signed by Chief District Judge Thomas S. Kleeh on 12/23/2024. (snc) (Entered: 12/23/2024) (2) |
| Dec 23, 2024 | 45 | STIPULATION AND [PROPOSED] ORDER TO MODIFY DEADLINE FOR PLANNING MEETING REPORT by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited. (O'Brien, William) (Entered: 12/23/2024) (2) |
| Dec 20, 2024 | 44 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited Defendants Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1). (Copland, Gordon) (Entered: 12/20/2024) (1) |
| Dec 18, 2024 | 43 | CERTIFICATE OF SERVICE by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs' Rule 26(a) Initial Disclosure Statement. (Pogue, David) (Entered: 12/18/2024) (1) |
| Dec 17, 2024 | 42 | JOINT STIPULATION AND ORDER TO MODIFY DEADLINE FOR PLANNING MEETING REPORT. The Court ORDERS that the deadline for the parties' Initial Planning Meeting Report and Scheduling Order Checklist is extended to December 23, 2024. Signed by Chief District Judge Thomas S. Kleeh on 12/17/2024. (jb) (Entered: 12/17/2024) (2) |
| Dec 16, 2024 | 41 | STIPULATION AND [PROPOSED] ORDER TO MODIFY DEADLINE FOR PLANNING MEETING REPORT by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Pharma GmbH & Co. KG. (Pogue, David) (Entered: 12/16/2024) (2) |
| Dec 6, 2024 | 40 | JOINT STIPULATION AND ORDER TO MODIFY DEADLINE FOR PLANNING MEETING REPORT. Deadline for the parties' Initial Planning Meeting Report and Scheduling Order Checklist is extended to December 16, 2024. Signed by Chief District Judge Thomas S Kleeh on 12/6/2024. (dk) (Entered: 12/06/2024) (2) |
| Dec 6, 2024 | 39 | STIPULATION AND [PROPOSED] ORDER TO MODIFY DEADLINE FOR PLANNING MEETING REPORT by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Pogue, David) (Entered: 12/06/2024) (2) |
| Dec 3, 2024 | 38 | JOINT STIPULATION AND ORDER TO MODIFY DEADLINE FOR PLANNING MEETING REPORT. The Court ORDERS that the deadline for the parties' Initial Planning Meeting Report and Scheduling Order Checklist is extended to December 9, 2024. Signed by Chief District Judge Thomas S. Kleeh on 12/03/2024. (snc) (Entered: 12/03/2024) (3) |
| Nov 27, 2024 | 37 | STIPULATION AND [PROPOSED] ORDER TO MODIFY DEADLINE FOR PLANNING MEETING REPORT by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Pogue, David) (Entered: 11/27/2024) (3) |
| Nov 22, 2024 | 36 | Corporate Disclosure Statement by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. identifying Corporate Parent C.H. Boehringer Sohn AG & Co. KG for Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc... (Pogue, David) (Main Document 36 replaced with flattened document on 11/25/2024) (dk). (Entered: 11/22/2024) (2) |
| Nov 15, 2024 | 34 | ORDER granting 31 Motion for Leave to Appear Pro Hac Vice for Eliana Applebaum filed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation and Boehringer Ingelheim Pharma GmbH & Co. KG. Signed by Chief District Judge Thomas S. Kleeh on 11/15/2024. (jb) (Entered: 11/15/2024) (1) |
| Nov 15, 2024 | 35 | ORDER granting 32 Motion for Leave to Appear Pro Hac Vice for Christopher Ilardi filed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation and Boehringer Ingelheim Pharma GmbH & Co. KG. Signed by Chief District Judge Thomas S. Kleeh on 11/15/2024. (jb) (Entered: 11/15/2024) (1) |
| Nov 14, 2024 | 33 | Pro Hac Vice filing fee for Christopher Ilardi and Eliana Applebaum in the amount of $400.00 paid. Receipt Number: 100003969. (jb) (Entered: 11/14/2024) (0) |
| Nov 14, 2024 | 32 | MOTION for Leave to Appear Pro Hac Vice of Christopher Ilardi by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment A, # 2 Exhibit A-WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 11/14/2024) (0) |
| Nov 14, 2024 | 31 | MOTION for Leave to Appear Pro Hac Vice of Eliana Applebaum by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment A, # 2 Exhibit A-WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 11/14/2024) (0) |
| Nov 5, 2024 | 30 | ANSWER to 25 Answer to Amended Complaint,, Counterclaim, by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc..(Pogue, David) (Entered: 11/05/2024) (24) |
| Oct 18, 2024 | 29 | FIRST ORDER AND NOTICE REGARDING DISCOVERY AND SCHEDULING: ***NOTICE TO ATTORNEYS*** : Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, ALL Non-governmental CORPORATE parties must file a DISCLOSURE STATEMENT with the Court. Forms are available on the Court's Web Site at http://www.wvnd.uscourts.gov/forms.htm Rule 26 Meeting to be held by 11/18/2024. Rule 26 Meeting Report due by 12/2/2024. Discovery due by 12/18/2024. Signed by Chief District Judge Thomas S Kleeh on 10/18/2024. (dk) (Entered: 10/18/2024) (6) |
| Oct 16, 2024 | 27 | ORDER GRANTING MOTION TO SEAL (ECF NO. 26 ). The unredacted Defendants' Answer to Plaintiffs' Amended Complaint and Counterclaims [ECF No. 26-1] attached to the motion shall be SEPARATELY FILED UNDER SEAL. Signed by Chief District Judge Thomas S Kleeh on 10/16/2024. (dk) (Entered: 10/16/2024) (1) |
| Oct 15, 2024 | 25 | ANSWER to 12 Amended Complaint, **REDACTED PUBLIC VERSION, COUNTERCLAIM against Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc..(Copland, Gordon) (Entered: 10/15/2024) (30) |
| Oct 9, 2024 | 24 | ORDER APPROVING APPLICATIONS TO APPEAR PRO HAC VICE. The following pro hac vice applications are APPROVED and the applicants may appear pro hac vice in this matter: Deepro R. Mukerjee 19 ; Lance A. Soderstrom 20 ; and Joseph M. Janusz 22 . Signed by Chief District Judge Thomas S Kleeh on 10/9/2024. (dk) (Entered: 10/09/2024) (1) |
| Oct 8, 2024 | 23 | PHV Filing fee received for Joseph M. Janusz: $ 200.00, receipt number 100003955. (dk) (Entered: 10/08/2024) (0) |
| Oct 7, 2024 | 22 | MOTION for Leave to Appear Pro Hac Vice (Joseph M. Janusz) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 10/07/2024) (0) |
| Oct 3, 2024 | 21 | PHV Filing fees received for Attorneys L. Soderstrom and D. Mukerjee: $ 400.00. Receipt number 100003954. (dk) (Entered: 10/03/2024) (0) |
| Oct 2, 2024 | 20 | MOTION for Leave to Appear Pro Hac Vice (Lance A. Soderstrom) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 10/02/2024) (0) |
| Oct 2, 2024 | 19 | MOTION for Leave to Appear Pro Hac Vice (Deepro R. Mukerjee) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 10/02/2024) (0) |
| Sep 16, 2024 | 18 | NOTICE of Appearance by William J O'Brien on behalf of Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (O'Brien, William) (Entered: 09/16/2024) (2) |
| Sep 10, 2024 | 17 | ORDER APPROVING APPLICATIONS TO APPEAR PRO HAC VICE. The following pro hac vice applications are APPROVED and that the applicants may appear pro hac vice in this matter: 5 Motion of Sam Kwon for Leave to Appear Pro Hac Vice; 6 Motion of Jeanna Wacker for Leave to Appear Pro Hac Vice; 7 Motion of James Hurst for Leave to Appear Pro Hac Vice; 8 Motion of Tasha Francis Gerasimow for Leave to Appear Pro Hac Vice; 10 Motion of Bryan Hales for Leave to Appear Pro Hac Vice. Signed by Chief District Judge Thomas S Kleeh on 9/10/2024. (dk) (Entered: 09/10/2024) (1) |
| Sep 10, 2024 | 15 | ORDER GRANTING MOTION TO SEAL (ECF NO. 13 ). The Amended Complaint attached to the motion shall be SEPARATELY FILED UNDER SEAL, with its accompanying exhibits. Signed by Chief District Judge Thomas S Kleeh on 9/10/2024. (dk) (Entered: 09/10/2024) (1) |
| Sep 10, 2024 | 14 | REPORT to USPTO on the filing or determination of an action regarding re 12 Amended Complaint. (dk) (Entered: 09/10/2024) (1) |
| Sep 9, 2024 | 12 | Amended Complaint* (1) |
| Sep 6, 2024 | 11 | Filing fee: Pro Hac Vice fee received for Bryan S. Hales in the amount of $ 200.00, receipt number 500003637. (mas) Modified on 9/16/2024 to add Pro Hac Vice language (mas). (Entered: 09/06/2024) (0) |
| Sep 6, 2024 | 10 | MOTION for Leave to Appear Pro Hac Vice of Bryan S. Hales by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 09/06/2024) (0) |
| Sep 6, 2024 | 9 | Filing fee: Pro Hac Vice fee received for Sam Kwon, Jeanna M. Wacker, James F. Hurst and Tasha Francis Gerasimow in the amount of $ 800.00, receipt number 500003636. (mas) Modified on 9/16/2024 to add Pro Hac Vice language (mas). (Entered: 09/06/2024) (0) |
| Sep 6, 2024 | 8 | MOTION for Leave to Appear Pro Hac Vice of Tasha Francis Gerasimow by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 09/06/2024) (0) |
| Sep 6, 2024 | 7 | MOTION for Leave to Appear Pro Hac Vice of James F. Hurst by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 09/06/2024) (0) |
| Sep 6, 2024 | 6 | MOTION for Leave to Appear Pro Hac Vice of Jeanna M. Wacker by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 09/06/2024) (0) |
| Sep 6, 2024 | 5 | MOTION for Leave to Appear Pro Hac Vice of Sam Kwon by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 09/06/2024) (0) |
| Aug 30, 2024 | 4 | REPORT to USPTO on the filing or determination of an action regarding re 1 Complaint. (dk) (Entered: 08/30/2024) (1) |
| Aug 30, 2024 | 3 | VERIFICATION OF ATTORNEY ADMISSION to Attorneys Bryan S. Hales, James F. Hurst, Jeanna M. Wacker, Sam Kwon, and Tasha Gerasimow. (dk) (Entered: 08/30/2024) (1) |
| Aug 29, 2024 | 1 | COMPLAINT against All Defendants, filed by Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation. Filing Fee Paid $405. Receipt #AWVNDC-4002524. (Attachments: # 1 Exhibit 1 - U.S. Patent, # 2 Civil Cover Sheet) (dk) Modified to correct filing date on 9/18/2024. NEF regen. (dk). (Entered: 08/30/2024) (0) |
